Prothrombin Time

• 

  Subject Areas on Research

  • A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity. 
  • A multicenter study of anticoagulation parameters when using heparin and warfarin. 
  • A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA). 
  • Acquired hypoprothrombinemia: effects of danazol treatment. 
  • Acute pancreatitis and fulminant hepatic failure. 
  • Adaptive force sonorheometry for assessment of whole blood coagulation. 
  • An evaluation of patient self-testing competency of prothrombin time for managing anticoagulation: pre-randomization results of VA Cooperative Study #481--The Home INR Study (THINRS). 
  • Anticardiolipin antibodies and osteonecrosis of the femoral head. 
  • Association of Ozone Exposure With Cardiorespiratory Pathophysiologic Mechanisms in Healthy Adults. 
  • Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation. 
  • Clinical use of the activated partial thromboplastin time and prothrombin time for screening: a review of the literature and current guidelines for testing. 
  • Coagulation abnormalities and thrombosis in patients with COVID-19. 
  • Coagulation abnormalities in patients with hip osteonecrosis. 
  • Coagulation changes in elective surgery and trauma. 
  • Coagulation in Liver Disease. 
  • Coagulopathy in COVID-19. 
  • Coagulopathy is prevalent and associated with adverse outcomes in transfused pediatric trauma patients. 
  • Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. 
  • Controlled Multifactorial Coagulopathy: Effects of Dilution, Hypothermia, and Acidosis on Thrombin Generation In Vitro. 
  • Cross circulation between children in hepatic coma and chimpanzees. Clinical, biochemical, and coagulation observations. 
  • Decreased sensitivity to warfarin in patients with myxedema. 
  • Direct-to-patient expert system and home INR monitoring improves control of oral anticoagulation. 
  • Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures. 
  • Disseminated intravascular coagulation in association with pig-to-primate pulmonary xenotransplantation. 
  • Do anticoagulation management services improve care? Implications of the Managing Anticoagulation Services Trial. 
  • Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study. 
  • Effects of antithrombin and heparin cofactor II levels on anticoagulation with Intimatan. 
  • Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation. 
  • Erythromycin-induced digoxin toxicity. 
  • Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro. 
  • Evaluation of p-amidinophenyl esters as potential antithrombotic agents. 
  • First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. 
  • Fully printed prothrombin time sensor for point-of-care testing. 
  • Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation. 
  • How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. 
  • Hypercalcemia. A complication of advanced chronic liver disease. 
  • Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. 
  • In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry. 
  • International normalized ratio. 
  • Long-term follow-up of auxiliary orthotopic liver transplantation for the treatment of fulminant hepatic failure. 
  • Magnetic resonance imaging and hepatic hemodynamics: correlation with metabolic function in liver transplantation candidates. 
  • Malfunction of the liver after transplantation: an analysis of potential risk factors. 
  • Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. 
  • Monitoring warfarin therapy in patients with lupus anticoagulants. 
  • Point-of-care testing of the international normalized ratio in patients with antiphospholipid antibodies. 
  • Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF. 
  • Prediction of Early Death in Patients With Sepsis-Associated Coagulation Disorder Treated With Antithrombin Supplementation. 
  • Pretransplant status and patient survival following liver transplantation. 
  • Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. 
  • Procoagulant and platelet aggregating properties of antilymphocyte sera. 
  • Prophylactic correction of the international normalized ratio in neurosurgery: a brief review of a brief literature. 
  • Proposal of a two-step process for the diagnosis of sepsis-induced disseminated intravascular coagulation. 
  • Protective effects of ischemic preconditioning for liver resection performed under inflow occlusion in humans. 
  • Prothrombin and beta 2-glycoprotein I frequently contribute to antiphospholipid antibody interactions with phospholipids and the generation of abnormal waveform profiles in coagulation assays. 
  • RE: The prothrombin time ratio is not a more effective marker for evaluating sepsis-induced coagulopathy than fibrin-related markers: Response to the Letter-to-the-Editor by Dr Wada. 
  • RNA aptamers as reversible antagonists of coagulation factor IXa. 
  • Response to warfarin in hypothyroid rats. 
  • Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. 
  • Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers. 
  • Spontaneous evolution in bilirubin levels predicts liver-related mortality in patients with alcoholic hepatitis. 
  • Ten-year results with the St. Jude Medical prosthesis. 
  • The anticoagulant effect of protamine sulfate is attenuated in the presence of platelets or elevated factor VIII concentrations. 
  • The coagulation cascade in cirrhosis. 
  • The effect of temperature variation in vitro on platelet-leukocyte interactions and individual prothrombotic potential. 
  • The impact of frequency of patient self-testing of prothrombin time on time in target range within VA Cooperative Study #481: The Home INR Study (THINRS), a randomized, controlled trial. 
  • The impact of patient self-testing of prothrombin time for managing anticoagulation: rationale and design of VA Cooperative Study #481--the Home INR Study (THINRS). 
  • The kaolin-activated Thrombelastograph predicts bleeding after cardiac surgery. 
  • The use of recombinant activated factor VII in three patients with central nervous system hemorrhages associated with factor VII deficiency. 
  • Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. 
• 

  Keywords of People

  • Levy, Jerrold Henry, Professor of Anesthesiology, Anesthesiology, Cardiothoracic